Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…